semaglutide ashburn Weight Loss Therapies VA: Real, Lasting Results February is YOUR month to

Renal Impairment- TRESIBA pharmacokinetics was studied in 32 subjects (N=4-8/group) with normal or impaired renal function/end-stage renal disease following administration of a single subcutaneous dose (0.4 units/kg) of TRESIBA

The difference is cost, access, and how medication is filled

Testing transparency Testing is referenced, but batch-level traceability and clearly accessible third-party documentation are limited

At REVIV were the global leader when it comes to IV wellness and to date weve delivered over 500,000 therapies worldwide

5 Figure 3: Pharmacy claims data show that 63% of patients initiating Wegovy or Zepbound in early 2024 remained on therapy at one year, up from 40% in the 2023 cohort